$PGEN

Shah Rutul R sold $186K of PGEN

Shah Rutul R (Chief Operating Officer) sold 42,703 shares of PRECIGEN, INC. (PGEN) at $4.36 ($0.19M total) on 2026-05-28.

Original reporting
SEC EDGAR · Shah Rutul R
Published Jun 1, 2026, 8:27 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 1, 2026, 8:39 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$PGEN
Neutral
medium confidence
Mentioned
$PGEN
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PGENNeutralLow
01

Why it matters

The disclosed sale can influence short-term sentiment, but it does not introduce new company fundamentals or catalysts.

02

Market read

Traders may monitor for follow-on insider activity or concurrent fundamental news; otherwise impact is likely limited.

03

What to watch

No 10b5-1 plan context is provided in the article; without knowing whether sales are routine, the signal-to-noise for interpreting bearish intent is weak.

Relevance 6/10Novelty 6/10Timing: Filed June 1; sale executed May 28 (post-transaction disclosure window).

Background

The article reports an SEC Form 4 insider transaction for Precigen, Inc. (PGEN), identifying the COO and the sale details.

Company-level read

Ticker impact

$PGENNeutralMedium confidence
Context

Pre-gen COO Shah Rutul R sold 42,703 shares in an open-market transaction, disclosing $186,185 in proceeds via SEC Form 4.

Expected impact

Low likelihood of a sustained price move; any reaction is likely short-lived unless followed by additional insider activity or fundamental updates.

Evidence & confidence

The filing is a disclosed sale with no accompanying company-specific operational news (earnings, trial, contract, financing). Insider sales are common and often pre-planned; the article also does not provide intent or context beyond the transaction details.

Market effects

Limited read-across to biotech/clinical-stage sentiment; insider sale alone typically does not reset sector expectations.

None specific beyond US small/mid-cap biotech sentiment.

Minimal; this is company-specific insider activity with no stated global catalyst.

Counterpoint

Because the sale is disclosed after execution and may reflect diversification or liquidity needs, the market may overreact relative to the actual signal strength.

Key entities

  • PRECIGEN, INC.

    Subject of the SEC Form 4 insider transaction disclosure.

  • Shah Rutul R

    Chief Operating Officer who sold 42,703 shares on May 28.

Related articles

$PGENMed

PRECIGEN, INC. (PGEN): Results of Operations and Financial Condition

PRECIGEN, INC. (PGEN) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 dp251262_ex9901.htm EXHIBIT 99.1 Exhibit 99.1 Precigen Reports Second Quarter 2026 Financial Results Highlighted by Accelerating PAPZIMEOS Revenue Growth · PAPZIMEOS ® net revenue of $53.1 million in the second quarter of 2026, more than double the prior quarter, reflec

$PGENMedAI 9/10

Precigen Presents New Long-Term Durability Data for PAPZIMEOS, Recently Granted Seven-Year Market Exclusivity, Demonstrating Complete Responses Beyond 4 Years

Precigen (Nasdaq: PGEN) reported updated long-term durability data for PAPZIMEOS (zopapogene imadenovec-drba) in adults with recurrent respiratory papillomatosis. According to the company, 15 of 18 complete responders (83%) had ongoing complete responses for at least 36 months as of April 30, 2026, with 5 beyond 4 years; median duration not yet reached and no new safety events were observed. The FDA granted seven-year orphan drug market exclusivity.

$PGENMedAI 9/10

Precigen Presents New Long-Term Durability Data for PAPZIMEOS, Recently Granted Seven-Year Market Exclusivity, Demonstrating Complete Responses Beyond 4 Years

Precigen (Nasdaq: PGEN) reported updated long-term durability data for PAPZIMEOS (zopapogene imadenovec-drba) in adults with recurrent respiratory papillomatosis (RRP), presented at the 2026 ASCO meeting. As of April 30, 2026, 15 of 18 complete responders (83%) had ongoing complete responses for ≥36 months without additional RRP treatment; 5 responders had responses beyond 4 years. Precigen said no new adverse safety events were observed. The FDA granted PAPZIMEOS seven-year orphan drug market e